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OBJECTIVE We analyzed the results of intravenous thrombolytic treatment under transesophageal
echocardiographic (TEE) guidance in prosthetic valve thrombosis.
BACKGROUND Thrombotic occlusion of prosthetic valves continues to be an uncommon but serious
complication. Intravenous thrombolytic treatment has been proposed as an alternative to
surgical intervention.
METHODS In a four-year period, 32 symptomatic patients with prosthetic valve related thrombosis
underwent 54 thrombolytic treatment sessions for the treatment of 36 distinct episodes. All
patients had low international normalized ratio values at the presentation. Transesophageal
echocardiography was performed at baseline and repeated after each thrombolytic treatment
session (total 98 TEE examinations). Streptokinase was used as the initial agent with a repeat
dose given within 24 h when necessary. Recurrent thrombosis was treated either with tissue
plasminogen activator or urokinase.
RESULTS The initial success after first dose was only 53% (17/32) but increased up to 88% (28/32) after
repeated thrombolytic sessions upon documentation of suboptimal results on TEE exami-
nation (p , 0.01). In addition, four asymptomatic patients with large thrombi were also
successfully treated with single infusion. The TEE characteristics of thrombus correlated with
clinical presentation and response to lytics. Success was achieved with single lytic infusion in
40% of the obstructive thrombi as compared with 75% of the nonobstructive ones (p , 0.05).
The success rates of lytic treatment were similar for mitral versus aortic valves, and for tilting
disk versus bileaflet valves. Rapid (3 h) and slow (15 to 24 h) infusion of streptokinase resulted
in similar success rates. However, major complications (three patients) occurred only in the
rapid infusion group.
CONCLUSION In patients with prosthetic valve thrombosis, intravenous slow infusion thrombolysis given in
discrete, successive sessions guided by serial TEE and transthoracic echocardiography can be
achieved with a low risk of complications and a high rate of success. (J Am Coll Cardiol
2000;35:1881–9) © 2000 by the American College of Cardiology
Thrombotic prosthetic valve occlusion is an uncommon but
serious complication that has been reported to occur in 0.5%
to 8% of the left-sided mechanical prosthetic valves and in
up to 20% of tricuspid prostheses (1–3). Surgical thrombec-
tomy and valve replacement have been used routinely for
this condition, although the operative mortality was quite
high in certain subsets (4,5). Intravenous lytic treatment for
thrombosed prosthetic valves has been used as an alternative
to surgical thrombectomy and valve replacement (6–31). In
recent years, transesophageal echocardiography (TEE) has
greatly improved the detection of intracardiac thrombus and
valve dysfunction (32–34). Likewise, several authors (35–
38) have recommended the use of TEE in the management
of thrombotic prosthetic valve occlusions. However, the
indications and delivery methods for thrombolytic treat-
ment in prosthetic valve thrombosis have not been well
defined. Recently, new treatment algoritms have been pro-
posed in two publications (29,30). The new American
College of Cardiology/American Heart Association (ACC/
AHA) guidelines on valvular disease (39) essentially
adopted the approach proposed in these articles, with more
emphasis on the potential side effects of thrombolysis. The
knowledge base for the thrombolytic treatment of prosthetic
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valve thrombosis is mostly derived from heterogeneous
patient series and anecdotal evidence. Therefore, the ques-
tions remain regarding the selection of patients according to
the thrombus characteristics, the duration and dose of the
thrombolytic treatment, the proper monitoring method and
the role of intensified anticoagulation as compared with
early thrombolysis.
In the present study, we analyzed the results in a
consecutive series of patients with prosthetic heart valves in
whom the thrombolytic treatment was administered in
discrete, successive treatment sessions guided by serial TEE.
The success and the complication rates were analyzed
according to the echocardiographic and clinical characteris-
tics of the patients.
METHODS
The study group included 32 consecutive symptomatic
patients with mechanical heart valves (13 male, 19
female; average age, 36 6 12 years) who underwent 54
intravenous thrombolytic treatment sessions in the same,
single institution between May 1993 and June 1997 for
the treatment of 36 distinct valvular thrombotic events
(one involving two valves in the same patient). In 6 of
these 32 patients, an additional left atrial mural thrombus
was also present. These events involved either hemody-
namically significant thrombotic valvular obstruction or
large valvular thrombus formation with embolic events
despite normal valve function (Table 1). In addition, 4
asymptomatic patients (2 male, 2 female) with mechan-
ical heart valves and large (.10 mm in diameter) thrombi
were analyzed separately, thus bringing the total number
of patients to 36.
The TEE was performed using 5-MHz multiplane trans-
ducer connected to a system (Vingmed CFM 800) after
oropharyngeal anesthesia (10% lidocaine) and conscious
sedation (intravenous midazolam, 1 to 3 mg). Transthoracic
echocardiography (TTE) to supplement gradient and valve
area calculations was performed using the same system with
3.25-MHz transducers. All echocardiographic examinations
were performed at baseline and repeated after each throm-
bolytic treatment session (total 98 TEE examinations).
Each recording was initially evaluated by two echocardio-
graphers independently and the consensus by both reviewers
was achieved in a subsequent session. The protocol was
approved by the Institutional Review Board. Written in-
formed consent was obtained from each patient before entry
into the study.
Echocardiographic criteria. The echocardiographic data
used in this study were as follows: prosthetic valve thrombus
was recognized as soft and homogeneous, mobile or fixed
echo densities located at the valve occluder and/or valve
struts. The largest diameter of the thrombus as well as the
length of the mobile portion, if present, were measured. A
diagnosis of pannus formation was made when fixed, bright
echodense structures, sometimes containing focal calcific
deposits, were present primarily along the valve ring with
extension into the valve orifice. Patients with valve dysfunc-
tion due to pannus formation were not included in this
series (four patients in the same time period, all confirmed
at surgery).
Although different makes of mechanical valves will have
different “normal gradient” ranges, we arbitrarily selected
the cutoff points for valvular obstruction. These limits were
largely based on the previously published values (40). Since
we did not have a baseline recording for each valve, more
specific cutoff points could not be determined. The limita-
tion of the occluder movement was evaluated subjectively. A
significant narrowing of the prosthesis was diagnosed when
the Doppler mitral valve area was #1.5 cm2 and the mitral
valve mean gradient was $10 mm Hg, or when the aortic
mean gradient was $40 mm Hg.
Thrombolytic treatment. Patients with obstructive throm-
bus, and those with nonobstructive thrombus, who either
had a history of embolization or had a large thrombus mass
($10 mm base diameter and/or $5 mm mobile segment
length) were accepted as candidates for thrombolysis. Pa-
tients with large thrombus were not excluded. Thrombolytic
treatment was contraindicated in patients with bleeding
tendency and in those with expanding or hemorrhagic
cerebral infarcts.
Streptokinase (SK) was the initial agent infused in all
patients. No loading dose of SK was used. In the early
experience (15 patients), a total of 1.5 million units of SK
was administered in 3 h. In subsequent patients, a slow
infusion of 60,000 to 100,000 U/h for a total of 15 to 24 h
was given (Table 2). When the persistence of thrombus was
documented by repeated TEE, another infusion of 1.5
million units of SK was given. Urokinase (UK) or tissue
plasminogen activator (tPA) (depending on the availability)
was chosen for recurrent thrombus or in the case of
failure of two subsequent SK sessions. The tPA dose was
100 mg (10-mg bolus followed by the infusion of the
remaining amount in 5 h). The UK dose for each session
was 1.5 million units given as a 15-h continuous infusion
(100,000 U/h).
Abbreviations and Acronyms
ACC/AHA 5 American College of
Cardiology/American Heart Association
CT 5 computed tomography
INR 5 international normalized ratio
NYHA 5 New York Heart Association
SKZ 5 streptokinase
TEE 5 transesophageal echocardiography
tPA 5 tissue plasminogen activator
TTE 5 transthoracic echocardiography
UK 5 urokinase
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Definition of thrombolytic success. The response to throm-
bolytic treatment was defined as a complete success when
significant narrowing of the valve (based on hemodynamic
measurements mentioned above) was no longer present and a
$75% reduction in largest diameter of the thrombus mass was
achieved. For nonobstructive thrombi, a reduction by $75% in
thrombus diameter or complete lysis of the mobile portion of
the thrombus was required as criteria for complete success. The
positive responses that were less than “completely successful”
were accepted as partial success.
Heparin and warfarin treatment was started in patients
with complete and partial success and heparin therapy was
continued until an international normalized ratio (INR) of
$2.5 was achieved.
Table 1. Summary of 36 Patients With Prosthetic Valve Thrombosis
No
Age (yr),
Gender Valve Type
Thrombus
Type
NYHA
Class
Presenting
Symptoms Agent Protocol Efficacy
Overall
Complications
1. 31, F Mi, SO ML FO IV Dyspnea SKZ Slow S No
2. 30, M Ao, MT ML MNO II C. embolism SKZ Slow S No
3. 37, F Mi, SJ BL MNO II C. embolism SKZ Rapid S No
4. 30, M Mi, SO ML FO III Dyspnea SKZ x21rt-PA Rapid F No
5. 52, F Mi, CM BL FO IV Dyspnea SKZ x2 Rapid S No
6. 47, F Mi, SO BL MNO III Dyspnea SKZ Slow S No
7. 55, M Mi, SO ML FO IV Dyspnea SKZ x2 Rapid S No
8. 41, M Mi, SJ BL MNO I C. embolism SKZ Rapid S No
9. 25, M Mi, SJ BL FO IV Dyspnea SKZ Rapid S Epistaxis
10. 49, M Ao, BS ML FO II Fever SKZ Rapid S No
11. 46, F Mi, BS ML MNO I C. embolism SKZ Rapid S No
12. 40, F Ao, SJ BL FO II C. embolism SKZ Rapid S AMI
13. 20, F Mi, UL ML MO III TIA SKZ x2 Slow S No
14. 68, F Ao, DM BL MNO I C. embolism SKZ Slow S No
15. 28, M Ao, MT ML FO III P. embolism SKZ x2 Rapid S No
16. 25, M Ao, MT ML FO II Dyspnea SKZ x2 Slow F No
17. 34, F Mi, UL ML FO III Loss of VS SKZ Slow S Vaginal
hemorrhage
1st ReTHR FO III Dyspnea rt-PA S
2nd ReTHR FO II Dyspnea rt-PA x2 S
18. 41, F Mi, UL ML FO III Loss of VS SKZ x2 Slow S No
19. 28, M Mi, SO ML MNO I TIA SKZ Rapid S No
20. 48, F Mi, SO ML FO III Dyspnea SKZ Rapid S C. embolism
21. 44, M Mi, SJ BL MNO II TIA SKZ x2 Rapid F No
22. 25, M Mi, CM BL FO III Loss of VS,
Dsypnea
SKZ x2 Rapid S No
Ao, CM BL MO Dyspnea
23. 31, F Mi, SO ML FO III P. embolism SKZ Slow S Epistaxis
24. 31, F Mi, SJ BL MO III Dyspnea SKZ x2 Slow S No
Re THR MNO II Dyspnea UK x2 S
25. 36, F Mi, MT ML MNO II C. embolism SKZ x2 Slow S No
ReTHR MNO II Dyspnea rt-Pa S
26. 31, F Ao, MT ML FO III Dyspnea SKZ Slow S No
27. 30, F Mi, SJ BL FO II Dyspnea SKZ x2 Slow S No
28. 36, F Mi, ATS BL FO II Dyspnea SKZ Slow S No
29. 37, M Mi, SJ BL MNO I C. embolism SKZ Slow S No
30. 23, F Mi, UL ML MO IV Dyspnea SKZ x2 Rapid F Death
31. 51, M Mi, UL ML FO III Dyspnea SKZ x2 Slow S No
32. 38, F Tri, SJ BL FO II Loss of VS rt-Pa x2 S No
33. 27, M Mi, SO ML MNO I Asympt. SKZ Rapid S No
34. 64, M Mi, SO BL FNO I Asympt. SKZ Slow S No
35. 55, F Mi, SO BL MNO I Asympt. SKZ Slow S No
36. 69, F Mi, SO BL FNO I Asympt. SKZ Slow S No
Abbreviations: F 5 female; M 5 male; Mi 5 mitral; Ao 5 aortic; Tri 5 tricuspid valve; ML 5 monoleaflet; BL 5 bileaflet; SO 5 Sorin; MT 5 Medtronic-Hall; SJ 5
St. Jude; DM 5 Duromedics; BS 5 Bjo¨rk-Shiley; UL 5 Ultracor; CM 5 Carbomedics; F 5 fixed; M 5 mobile; O 5 obstructive; NO 5 nonobstructive; SKZ 5
streptokinase; rt-PA 5 recombinant tissue type plasminogen activator; UK 5 urokinase; lytic agent name x2 indicates that two successive doses were administered; S 5
success; F 5 failure; ReTHR 5 rethrombosis; VS 5 valve sound; Asympt. 5 asymptomatic; C 5 cerebral; P 5 peripheral; TIA 5 transient ischemic attack; AMI 5
acute myocardial infarction.
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Statistical analysis. Chi-square test and Student’s t test
were utilized for the comparison of discrete and continuous
variables, respectively. A p value of ,0.05 was accepted as
significant.
RESULTS
The types of the prosthetic valves and clinical status at
presentation were summarized in Table 1. Of the 32
symptomatic patients, 23 had mitral, 7 had aortic and 1 had
tricuspid valve prostheses. In one patient thrombus compli-
cated both aortic and mitral prostheses. The etiology of
valve disease was rheumatic in all patients. The types of
prosthetic valves were 13 tilting disks and 11 bileaflet valves
in mitral position, and 5 tilting disks and 3 bileaflet valves in
aortic position. The only tricuspid prosthesis in this series
was a bileaflet design. The average interval between valve
replacement and presentation was 133 6 132 weeks (1 to
Table 2. Hemodynamic Measurements at Baseline and Following Final Thrombolysis Session
Case No.
Mean Gradient
(mm Hg)
Mitral Valve Area
(cm2)
Valve
Thrombus
TypeBefore Final Before Final
1. 12 5 1.3 2.7 Mitral FO
2. 22 22 — — Aortic MNO
3. 3.8 3.6 2.6 2.6 Mitral MNO
4. 12 10 1.3 1.4 Mitral FO
5. 10.2 4 1 1.8 Mitral FO
6. 6 5.4 2.6 2.6 Mitral MNO
7. 13 3.5 0.8 2.4 Mitral FO
8. 3 2.9 2.5 2.5 Mitral MNO
9. 26 5.5 0.7 2.5 Mitral FO
10. 42 17 — — Aortic FO
11. 5.2 5 2.2 2.2 Mitral MNO
12. 65 14 — — Aortic FO
13. 10 4 1.5 2.5 Mitral MO
14. 17 15 — — Aortic MNO
15. 48 22 — — Aortic FO
16. 47 41 — — Aortic FO
17. 25 2.3 0.7 2.8 Mitral FO
rethromb. 23 2.5 0.8 3 FO
rethromb. 15 2.1 1 3.1 FO
18. 17 2 0.85 2.5 Mitral FO
19. 6 5.5 3 3.1 Mitral MNO
20. 19 2.8 1.02 3 Mitral FO
21. 2 2 2.8 2.8 Mitral MNO
22. 24 4 1.4 2.8 Mitral FO
22. 47 19 — — Aortic MO
23. 13 2.5 1.4 3.5 Mitral FO
24. 9 3.4 0.9 1.9 Mitral MO
rethromb. 3 3 1.8 1.8 MNO
25. 5 4.3 2.4 2.7 Mitral MNO
rethromb. 3 3.2 2.6 2.6 MNO
26. 52 18 — — Aortic FO
27. 17 3 1 2.9 Mitral FO
28. 30 3.2 0.8 2.5 Mitral FO
29. 3.2 3.2 3.2 3.2 Mitral MNO
30. 10 6 1.4 1.8 Mitral MO
31. 18 4.5 1 2.7 Mitral FO
32. 7.5 2.1 1* 3.2* Tricuspid FO
33. 3.5 3.7 2.5 2.5 Mitral MNO
34. 3 3 2.8 2.8 Mitral FNO
35. 5 3.5 2.8 2.9 Mitral MNO
36. 3.5 3 2.8 2.8 Mitral FNO
Patients are listed in the same order as in Table 1. Abbreviations are same as in Table 1. (*) tricuspid valve area. Rethromb. 5
Hemodynamic values recorded at the time of rethrombosis for the same patient.
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624 weeks; median, 103 weeks). In 4 of 32 patients (12.5%),
recurrent thrombus was documented 20 6 6 weeks (median,
20 weeks) after initially successful thrombolysis. One of
these four patients had a third recurrence 22 weeks after the
last one. Of note, all patients had subtherapeutic INR values
at the presentation (1.3 6 0.3). Recurrent thrombotic events
were also associated with low INR values. Atrial fibrillation
was present in 19 of 36 patients (53%).
The symptoms at presentation (Table 1) of 36 distinct
clinical episodes in 32 patients were mainly dyspnea (58%)
and embolic events or transient ischemic attacks (36%).
Interestingly, four patients reported muffling or cessation of
their prosthetic valve sounds. The New York Heart Asso-
ciation (NYHA) functional class was III or greater in 50%
of the episodes.
The number and the type of treatment sessions are also
shown in Table 1. In the mitral position, 41 thrombolytic
sessions (including 4 recurrent thrombus) were performed in
27 episodes in 23 patients. In aortic position 9 thrombolytic
sessions were given for 7 episodes in 7 valves. The patient
with both aortic and mitral valve thrombi was given SK in
two successive sessions. The patient with tricuspid prosthe-
sis previously had SK infusion at another institution and was
presented with recurrence (14). Doppler hemodynamic
measurements before and after the final session of throm-
bolytic treatment were listed in Table 2.
The outcome of thrombolytic treatment. According to
the study definitions, four episodes resulted in partial
success (Table 3). These were included in the complete
success group for their small numbers. The initial rate of
success after the first dose of SK in primary valvular
thrombosis was only 53% (17/32), but increased up to
87.5% (28/32) after repeated thrombolytic sessions upon
documentation of suboptimal results on TEE examination
(p , 0.01). One additional thrombolytic session was ad-
ministered in 17 episodes. A total of three thrombolytic
sessions were necessary in only one patient, who had an
unsuccessful result. In four patients with five episodes of
recurrent thrombosis, a single dose was successful in two
and two successive treatments were necessary in the remain-
ing three. Of the three patients with no response to lytics,
two were maintained on regimens of higher-dose oral
anticoagulants and the third one underwent surgery.
The initial and overall success rates of thrombolytic
treatment in mitral and aortic valves were 50% and 63%, and
87.5% and 87.5%, respectively (p 5 NS). The overall
success rates in tilting disk and bileaflet valves were 86% and
94%, respectively (p 5 NS). The success rates for throm-
bolysis were 89%, 92% and 80% in patients with NYHA
class #II, III and IV symptoms, respectively (p 5 NS).
There was no difference in success rate for rapid as com-
pared with slow infusion of SK (Table 4).
Echocardiographic thrombus characteristics and throm-
bolytic response. Baseline TEE results for each valve in
the symptomatic initial (n 5 32) and recurrent (n 5 5)
thrombotic episodes were analyzed together (total 37 valve-
episodes) (Table 5). Interobserver agreement was achieved
in 96 of 98 TEE recordings (98%) regarding the diagnosis
of thrombus and definition of its characteristics. Thrombus
characteristics were correlated with clinical presentation. A
fixed thrombus mass measuring at least 10 mm at its base
was documented in 21 episodes (57%) of which all were
associated with hemodynamically significant valvular ob-
struction. In contrast, a mobile thrombus with significant
motion of the thrombus mass (average length, 12.1 6
5.5 mm; 5 to 22 mm), regardless of the size, was found in
16 episodes (43%), and it was associated with valvular
obstruction in only 4 (25%, p , 0.001). However, mobile
thrombi were found in 10 of 13 discrete episodes that were
presented with embolic events (77%), while only 6 of 24
(25%) episodes without embolism were associated with
mobile thrombi (p , 0.05). Nonobstructive thrombi were
smaller (8.6 6 5.3 mm vs. 17.6 6 7.6 mm, p , 0.001) and
they were less likely to be associated with class III or greater
symptoms at presentation as compared with the obstructive
thrombi (8% vs. 71%, p , 0.001).
After the initial thrombolytic dose, complete success was
achieved in 10 of the 25 (40%) obstructive thrombi. In nine
more instances, thrombus was lysed enough to become
nonobstructive and in the remaining six, it continued to be
Table 3. Comparison of Thrombolytic Success for the Initial and Subsequent Doses of
Thrombolytics According to Valve Type and Location
Initial Thrombolytic
Success (%)
Subsequent Thrombolytic
Success (%)
Overall
Success (%)
Primary
Mitral 12/24 (50%) 9/12 (75%) 21/24 (87.5%)
Aortic 5/8 (62.5%) 2/3 (66.6%) 7/8 (87.5%)
Total 17/32 (53%) 11/15 (73.3%) 28/32 (87.5%)
Rethrombosis
Mitral 2/4 (50%) 2/2 (100%) 4/4 (100%)
Tricuspid 0/1 1/1 (100%) 1/1 (100%)
Total 2/5 (40%) 3/3 (100%) 5/5 (100%)
Overall 19/37 (51%) 14/18 (78%) 33/37 (89%)
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obstructive despite some (n 5 4) or no (n 5 2) change in
appearance. Complete success was confirmed in 12 of these
15 episodes after repeated administration of thrombolytics,
bringing the total success rate to 88% (22/25). Among the
12 nonobstructive thrombi, however, complete success was
achieved in 9 (75%) at the initial thrombolysis attempt (p ,
0.05, as compared with obstructive thrombi). The remain-
ing three patients with nonobstructive thrombi were given a
second dose of thrombolytics with success in two, thus
bringing the overall success in this subset to 91.6%. The
overall success rates in fixed (90.5%) and mobile (87.5%)
thrombi were not statistically different.
Thrombolytic treatment in asymptomatic patients.
There were two male and two female patients with mitral
valve prostheses (three bileaflet, one tilting disk) who
underwent successful thrombolysis for large, nonobstructive
left atrial thrombi detected on routine examination (Table
1). The thrombi were mobile in two and fixed type in the
remaining two. A single SK infusion session was successful
in all four patients.
Left atrial mural thrombus associated with thrombosis of
the mitral valve prosthesis. The left atrial mural thrombus
persisted in six patients despite successful lysis of the
thrombus associated with the prothesis itself. No systemic
embolization was noted in this group.
Complications of thrombolytic treatment. The symp-
tomatic and asymptomatic groups of patients combined for
the analysis of complications. The complications of throm-
bolytic treatment were seen in 15% of the 40 total throm-
botic episodes in 36 patients (Table 1). Major complications
included death in one patient (2.8%), coronary embolization
in one patient (2.8%) and cerebral embolization in one
patient (2.8%). Both patients with embolization had large,
fixed, obstructive thrombi on TEE. Death was due to
cerebral bleeding in a patient with 10-day-old brain embo-
lism with no evidence of hemorrhagic infarct on baseline
computed tomographic (CT) scan. Minor bleeding was
noted in three (8.3%) of the episodes. Of interest, all major
complications occurred in the group that received the rapid
infusion of SK as initial treatment. No complications
occurred in four asymptomatic patients. No complications
occurred as a result of TEE examinations.
DISCUSSION
Our study showed that intravenous thrombolysis can be
achieved with a high success rate in all echocardiographic
subsets of prosthetic valve thrombosis by administering
thrombolytics in successive episodes. In slightly more than
half of the events, a single infusion of thrombolytic was
successful, and one additional infusion ensured a successful
result in about three-fourths of the remaining. Additional
infusions were required more often in patients with obstruc-
tive as compared with nonobstructive thrombus. The relief
of hemodynamic obstruction by thrombolysis can be mon-
itored simply by transthoracic Doppler echocardiography.
Fluoroscopy may also be useful by detecting the return of
valve occluder motion to normal range (22). In addition to
its fundamental value in detecting nonobstructive thrombus,
TEE may still provide additional valuable information in
other subsets of prosthetic valve thrombosis that may be
important in the treatment of individual patients. Although
the changes in thrombus mass generally mirrored the
hemodynamic changes in patients with obstructive thrombi,
in 4 of these 25 patients, initial thrombolysis caused
Table 4. Patient Characteristics in Rapid and Slow Streptokinase Infusion Groups
SKZ Infusion
p ValueRapid Slow
Age (yr) 36 6 10.5 40.5 6 14 NS
Gender (F/M) (6/9) (12/4) NS
Bileaflet valve 7/15 (47%) 6/16 (37.5%) NS
Obstructive THR 10/15 (67%) 11/16 (69%) NS
THR diameter (mm) 13.8 6 8.4 15.2 6 6.8 NS
NYHA $III symptoms 8/15 (53.3%) 9/16 (56.3%) NS
Initial TT success 8/15 (53.3%) 9/16 (56.3%) NS
Subsequent TT success 4/7 (57.1%) 6/7 (85.7%) NS
Overall success 12/15 (80%) 15/16 (93.7%) NS
Abbreviations as in Table 1; TT 5 thrombolytic therapy; THR 5 thrombus.
Table 5. Comparison of Thrombolytic Success Rates According
to Transesophageal Echocardiography Characteristics of
Thrombus
Obstructive Nonobstructive
Initial thrombolysis success* 10/25 (40%) 9/12 (75%)
Subsequent thrombolysis
success
12/15 (80%) 2/3 (66.6%)
Overall success 22/25 (88%) 11/12 (91.6%)
Average no. of
thrombolytic sessions per
episode†
1.64 1.25
*p , 0.05; †p 5 0.04.
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reduction in the thrombus mass with no change in hemo-
dynamic obstruction. These four patients received addi-
tional thrombolytic infusions with relief of obstruction. In
three patients with no initial change in thrombus configu-
ration by TEE after the first thrombolytic dose, subsequent
doses also failed. Potentially, TEE may be useful in iden-
tifying these “resistant” cases. Nevertheless these are obser-
vations in small groups and the potential impact of serial
TEE in this context deserves to be investigated in larger
series.
Obstructive versus nonobstructive thrombus. Although
the hemodynamic benefit of lysing an obstructive thrombus
is obvious, the issue with nonobstructive prosthetic valve
thrombus is somewhat controversial. Recently published
guidelines by Lengyel et al. (30) proposed intensive antico-
agulation, rather than thrombolysis, in patients with non-
obstructive thrombi. Valvular thrombi without hemody-
namic obstruction can be detected with higher accuracy by
TEE (35) and may be seen in 15% to 18% of the patients in
the early postoperative period following valve replacement
(41). Despite the absence of hemodynamic embarrassment,
nonobstructive prosthetic thrombi may not be totally be-
nign. We and others showed that nonobstructive mobile
prosthetic valve thrombi carried an increased risk of sys-
temic embolization (35,41). In the current study, the
thrombolytic treatment was not associated with increased
embolic complications in this subset despite the more
frequent initial presentation with embolic events. Similarly,
a more recent study, again by Lengyel et al. (42), reported
that the anticoagulant treatment failed in half of the patients
with nonobstructive thrombi, while there was no failure or
complication in the group treated with thrombolysis. To-
gether these results bring strong support to extending the
indications for thrombolytic treatment to patients with
nonobstructive thrombi. Transesophageal echocardiography
may show persistent residual thrombus (with embolic po-
tential) following initial thrombolysis, even if the relief of
hemodynamic obstruction is detected by other means. In
our series, 9 of 25 (32%) obstructive thrombi were trans-
formed into nonobstructive but large thrombi (4 of them
gaining mobility) after the first SK dose and were treated
successfully with additional infusion of the thrombolytic in
all but one.
Thrombolysis results according to the valve type and
location. Roudaut et al. (20) reported higher thrombolytic
success rates for aortic than mitral prosthetic valves. Some
authors suggested that the bileaflet valve thrombotic occlu-
sions were more responsive to thrombolysis (20,23). An
explanation for this was the potential for the flow obstruc-
tion by a smaller thrombus occupying the critical pivot point
in a bileaflet valve as compared with a single disk valve. Our
series, in contrast, did indicate similar success rates in both
valve locations and valve types. This was true even when the
success rates for each valve location and type were further
stratified according to fixed or mobile, and obstructive or
nonobstructive thrombus characteristics.
Thrombolysis results according to the clinical status.
The thrombolytic success was achieved in equal proportion
of patients who were in class II or less as compared with
those who were in class III or greater. Hurrell et al. (29)
recommended direct surgical treatment rather than throm-
bolytics for patients with class IV symptoms, because of a
high medical mortality reported in some series. The ACC/
AHA valve disease guidelines (39) also recommended sur-
gical treatment in class IV patients except those who are
nonsurgical candidates. Unfortunately, the surgical mortal-
ity is also highest in this group of patients (4,5). Recently
published thrombolytic therapy guidelines (30) proposed
the thrombolytic treatment as the treatment of choice for
the “critically ill” patients in functional class III or IV,
although the definition of “critically ill” may be quite
variable. We believe that an individual approach based on
the expected surgical mortality rate is necessary in patients
with class IV symptoms. We suggest that, in the absence of
cardiogenic shock, these patients may be treated in the
intensive care unit by TEE-guided thrombolysis.
Systemic embolization and other complications. Due to
the lack of a generally accepted standard regimen, various
infusion protocols and thrombolytic doses were used in the
previous studies (6–31), making a direct comparison of the
results difficult. The rate of major events and minor bleeding
in our study was within the previously reported range. The
embolization rate of 5.7% (two patients) in our series
compares favorably with previously reported single institu-
tion series (Table 6). Both embolic complications occurred
in patients with fixed, obstructive thrombi who were given
rapid thrombolytic infusions. In the recent thrombolytic
treatment guidelines article (31), the presence of a large
thrombus on the prosthetic valve or in the left atrium has
been included in the relative contraindications based on one
case report of embolism following a rapid (3-h) infusion of
tPA (26). In a recent study by Manteiga et al. (31) 3
instances of embolization (33%) occurred in 10 patients
with large left atrial thrombi who were given rapid infusion
of SK (1.5 million units in 90 min). It appears that rapid
thrombolytic infusion, especially in the presence of large
thrombus, may increase the risk of embolization. Under-
standing the predictors of systemic embolism is important
because this complication seems to be the Achille’s heel of
the thrombolytic treatment of prosthetic valve thrombosis.
There are little data available on this subject. Reddy et al.
(24) published the series with lowest embolization rate and
suggested that advanced age and atrial fibrillation may be
the risk factors for embolic complications. Roudaut et al.
(20), however, found that class IV clinical status was the
only predictor of embolic complications (and death). It is
not known whether this was secondary to larger amounts of
thrombi in these patients.
The only mortality in our series was the result of cerebral
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bleeding in a patient with a 10-day-old cerebral embolism.
Although the baseline CT scan had not shown bleeding, a
repeated CT before second thrombolytic application might
have been important in this case. As a precaution, probably
no patient with cerebral embolism within 10 days should be
given thrombolytics and each patient should be carefully
assessed individually for the risk of hemorrhagic transfor-
mation of cerebral infarct.
CONCLUSIONS
In this series, intravenous thrombolysis for prosthetic valve
thrombosis was achieved with a low risk of complications
and a high rate of success in both obstructive and nonob-
structive prosthetic valve thrombosis. Thrombolytic treat-
ment was equally effective in both mitral and aortic valve
thrombi, and in both bileaflet and single disk valve designs.
We believe that the slow administration of intravenous
thrombolytics in discrete, successive sessions guided by
serial TEE and TTE information is a safe and effective
method that may expand the indications for nonsurgical
treatment of prosthetic valve thrombosis.
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